24Sep

New AbC-19™ COVID-19 antibody test developed by Abingdon Health and the UK-RTC

As demand for rapid testing continues to accelerate at an unprecedented level, our response to assisting testing on a global scale must be in place to support accurate, reliable and easy-to-use testing. 

The AbC-19™ COVID-19 antibody test developed by Abingdon Health and the UK-RTC, achieves 98.03% sensitivity and 99.5% specifically, will play an invaluable role in overcoming unpredicted rapid testing outcomes.


Download the whitepaper to learn:

  • How the body responds to SARS-COV-2
  • The different approaches to antibody testing
  • The UK-RTC Abc-19 Rapid Test
  • The link between antibodies and immunity
  • The route towards therapies and immunisation 

Please access the complete whitepaper for this device here.

Related

Genedrive Receives NHS Grant

The UK NHS National Institute for Health Research in June 2018 have offered Professor Bill Newman an...

Read More >

SpeeDx and Cepheid Announce Partnership on European Distribution

SYDNEY, AUSTRALIA -- 05/06/17 -- SpeeDx Pty, Ltd. today announced an agreement with Cepheid for dist...

Read More >

OGT further expands global direct sales and support into Asia-Pacific region

Following successful European rollout, more customers to benefit from enhanced local sales and suppo...

Read More >

DEMAND FOR GENETIC TESTING DRIVES GROWTH FOR AWARD WINNING ELUCIGENE DIAGNOSTICS

30 percent growth and innovation products wins Manchester company BVCA award. Having the right te...

Read More >